These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30519050)

  • 1. Association of MLH1 single nucleotide polymorphisms with clinical outcomes of first-line irinotecan-based chemotherapy in colorectal cancer.
    Wang D; Zhang X; Zhang Y; Wu Y; Guan X; Zhu W; Wang M; Qi C; Shen B
    Onco Targets Ther; 2018; 11():8083-8088. PubMed ID: 30519050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of transcription factor binding and epigenetic regulation of the MLH1 CpG island and shore by polymorphism rs1800734 in colorectal cancer.
    Savio AJ; Bapat B
    Epigenetics; 2017 Jun; 12(6):441-448. PubMed ID: 28304185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between MLH1 -93G>a polymorphism and risk of colorectal cancer.
    Wang T; Liu Y; Sima L; Shi L; Wang Z; Ni C; Zhang Z; Wang M
    PLoS One; 2012; 7(11):e50449. PubMed ID: 23226285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single nucleotide polymorphisms in
    Zhu X; Liu W; Qiu X; Wang Z; Tan C; Bei C; Qin L; Ren Y; Tan S
    Oncotarget; 2017 Oct; 8(45):80039-80049. PubMed ID: 29108386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer.
    Mrkonjic M; Roslin NM; Greenwood CM; Raptis S; Pollett A; Laird PW; Pethe VV; Chiang T; Daftary D; Dicks E; Thibodeau SN; Gallinger S; Parfrey PS; Younghusband HB; Potter JD; Hudson TJ; McLaughlin JR; Green RC; Zanke BW; Newcomb PA; Paterson AD; Bapat B
    PLoS One; 2010 Oct; 5(10):e13314. PubMed ID: 20967208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of hypoxia-related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF.
    Tang W; Liu X; Qiu L; Zhao X; Huang M; Yin J; Li J; Guo W; Zhu X; Chen Z
    Oncol Lett; 2018 Jan; 15(1):1334-1342. PubMed ID: 29399184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
    Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
    Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between MutL homolog 1 polymorphisms and the risk of colorectal cancer: a meta-analysis.
    Chen H; Shen Z; Hu Y; Xiao Q; Bei D; Shen X; Ding K
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2147-58. PubMed ID: 25986311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.
    Huang L; Zhang T; Xie C; Liao X; Yu Q; Feng J; Ma H; Dai J; Li M; Chen J; Zang A; Wang Q; Ge S; Qin K; Cai J; Yuan X
    PLoS One; 2013; 8(10):e77223. PubMed ID: 24143213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MLH1 rs1800734 Pathogenic Variant among Patients with Colorectal Cancer in the Lower Northeastern Region of Thailand.
    Pongsavee M; Wisuwan K; Pongsavee K
    Asian Pac J Cancer Prev; 2023 Aug; 24(8):2911-2916. PubMed ID: 37642081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
    Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
    Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW
    Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
    Berger MD; Stintzing S; Heinemann V; Yang D; Cao S; Sunakawa Y; Ning Y; Matsusaka S; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Soni S; Zhang W; Falcone A; Loupakis F; Lenz HJ
    Ann Oncol; 2017 Nov; 28(11):2780-2785. PubMed ID: 29045529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability.
    Russell H; Kedzierska K; Buchanan DD; Thomas R; Tham E; Mints M; Keränen A; Giles GG; Southey MC; Milne RL; Tomlinson I; Church D; Spurdle AB; O'Mara TA; Lewis A
    Clin Epigenetics; 2020 Jul; 12(1):102. PubMed ID: 32641106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
    Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Genetic Variant in
    Qin W; Zhao B; Wang D; Liu J; Zhou Y; Zhu W; Huang Y; Qiu H; Yuan X
    Front Oncol; 2022; 12():922342. PubMed ID: 35837092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.
    Yu Q; Zhang T; Xie C; Qiu H; Liu B; Huang L; Peng P; Feng J; Chen J; Zang A; Yuan X
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):87-98. PubMed ID: 29728798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dynamic DNA methylation landscape of the
    Savio AJ; Mrkonjic M; Lemire M; Gallinger S; Knight JA; Bapat B
    Clin Epigenetics; 2017; 9():26. PubMed ID: 28293327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.